LIMA, Peru – The infection-prevention potential of Lenacapavir,  the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, […] Continue reading ->
HIV activists have hailed the announcement by Gilead on Wednesday that it has authorised six generic manufacturers to sell its breakthrough HIV treatment, lenacapavir, in 120 low- and middle-income countries.  However, they have urged Gilead to expand the deal to include countries such as Brazil, Colombia and Mexico. Lenacapavir is a long-acting injectable drug that […] Continue reading ->
UNAIDS expressed “deep concern” Wednesday over Georgia’s newly adopted anti-LGBTQ+ law, saying that it could threaten progress made over the past decade to end AIDS in the former Soviet republic of 3.7 million people at the crossroads between Europe and Asia.  The new legislation exacerbates stigma and hinders “LGBTQ+ people’s access to essential health services” […] Continue reading ->
MUNICH – Delegates at the International AIDS conference leapt to their feet in delight after results from one of the most promising HIV prevention trial in the history of the epidemic – a twice-yearly injection of lenacapavir that prevented 100% of new HIV infections – were presented on Wednesday. Principal investigator Professor Linda-Gail Bekker from […] Continue reading ->
WHO’s Regional Director for Europe reflects on why we haven’t been able to end AIDS despite having the tools to do so – as Germany hosts the 25th International AIDS conference. Twenty-four years ago, Maria Godlevkskaya was in a coma in a hospital in Russia, her immune system having failed without treatment for her HIV. […] Continue reading ->